Analysis and data insight

The week's biggest gainers and losers

November 11, 2019

The top 10 biopharma stock gainers and losers for the week of Nov. 4-8, 2019.

BioWorld stock report for public biotechnology companies

November 11, 2019

All of the biopharma stocks tracked by BioWorld, including their weekly and year-to-date percent changes and weekly trading volumes.

In Latin America, Costa Rica is now a med-tech powerhouse

November 11, 2019

By Sergio Held

No Comments

SAN JOSE, Costa Rica – The tiny Latin American country that has become the region's second largest med-tech exporter behind Mexico is betting on disruptive technologies and trends to stay at the technological forefront. Costa Rica's med-tech exports have become one of the nation's most important sources of income and employment, and the country is focused on expanding the sector.

Zimmer Biomet shines in quarter as it continues to execute turnaround

November 6, 2019

By Liz Hollis

No Comments

Warsaw, Ind.-based Zimmer Biomet Holdings Inc. is moving ahead of schedule in terms of its turnaround as it reported revenue of $1.892 billion for the third quarter. That figure represents an increase of 3% over the same period last year, impressing analysts.

Tandem raises 2019 guidance on strength of its Q3 results

November 6, 2019

By Meg Bryant

No Comments

San Diego-based Tandem Diabetes Care Inc. reported financial results for the third quarter of 2019, with worldwide pump shipments soaring 112% to 17,839 pumps from 8,434 pumps in the same period a year ago. Revenue rose 105% to $94.7 million, up from $46.3 million in the third quarter of 2018.

Neurology ‘adapting’ to oncology model with new trial design

November 4, 2019

By Marie Powers

No Comments

The oncology field pioneered adaptive trial designs through efforts such as I-SPY 2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2), Puma Biotechnology Inc.’s phase II study of the pan-HER tyrosine kinase inhibitor neratinib (Nerlynx) as neoadjuvant therapy in metastatic breast cancer, and the ongoing multidrug, biomarker-driven non-small-cell lung cancer trial known as Lung-MAP.